EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT)
4.9900
-0.3800 (-7.08%)
NASDAQ · Last Trade: Apr 3rd, 9:12 PM EDT
Detailed Quote
Previous Close | 5.370 |
---|---|
Open | 5.020 |
Bid | 4.910 |
Ask | 5.130 |
Day's Range | 4.830 - 5.130 |
52 Week Range | 4.830 - 23.65 |
Volume | 929,868 |
Market Cap | 174.57M |
PE Ratio (TTM) | -2.151 |
EPS (TTM) | -2.3 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 794,870 |
Chart
About EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT)
Eyepoint Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments for diseases affecting the eye, particularly those related to retinal and intraocular conditions. The company is dedicated to advancing sustained-release drug delivery systems, enabling patients to receive extended therapeutic benefits from their medications with reduced frequency of administration. Eyepoint's portfolio includes specialized formulations that aim to improve patient outcomes and ease the burden of disease management in ocular health. Through its commitment to research and development, Eyepoint seeks to address unmet medical needs in the field of ophthalmology. Read More
News & Press Releases
Via Benzinga · March 14, 2025

Via Benzinga · March 6, 2025

Via Benzinga · February 18, 2025

Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Via Chartmill · February 5, 2025

Via Benzinga · February 5, 2025

Via Benzinga · October 28, 2024

Via Benzinga · August 13, 2024

Via Benzinga · May 7, 2024

EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients.
Via Benzinga · October 28, 2024

Via Benzinga · October 28, 2024

Via Benzinga · October 14, 2024

Via Benzinga · July 12, 2024

Via Benzinga · July 12, 2024

Via Benzinga · May 13, 2024

EYPT stock results show that EyePoint Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024

Via Benzinga · May 8, 2024

Via Benzinga · May 6, 2024

Via Benzinga · May 6, 2024

Via Benzinga · May 6, 2024

Via Benzinga · May 6, 2024

EyePoint Pharmaceuticals reveals Phase 2 PAVIA trial results for Duravyu in non-proliferative diabetic retinopathy. Positive data showcases Duravyu's efficacy and safety profile.
Via Benzinga · May 6, 2024